Title

Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to

Preoperative Radiotherapy and Surgery in SU2C-SARC032

Running Title

Sarcoma Microenvironment Predictors in SU2C-SARC032

Authors and Affiliations

Stefano Testa[1,#], Jonathon E. Himes[2,#], Ajay Subramanian[3], Serey C.L. Nouth[3], Karla V.

Ballman[4,5], Rachel S. Heise[6], Matthew Pierpoint[7], Neda Nemat-Gorgani[3], Timothy J. Sears[3],

Michael S. Binkley[3], Anusha Kalbasi[3], David L. Corcoran[8], Angela M. Hong[9,10], Brian E.

Brigman[11,12], Richard F. Riedel[12,13], Matt van de Rijn[14], Yvonne M. Mowery[12,15], Kent J.

Weinhold[12,16], David G. Kirsch[2,12,17,18,19,*], Everett J. Moding[3,20,*]

[1]Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical

School, Boston, Massachusetts, USA

[2]Department of Radiation Oncology, Duke University, Durham, North Carolina, USA

[3]Department of Radiation Oncology, Stanford University, Stanford, California, USA

[4]Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA

[5]Biostatistics Core, Sarcoma Alliance for Research through Collaboration, Ann Arbor, MI, USA

[6]Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA

[7]Department of Pharmacology & Cancer Biology, Duke University, Durham, North Carolina, USA

[8]Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, USA

[9]Department of Radiation Oncology, Chris O'Brien Lifehouse-Royal Prince Alfred Hospital,

Sydney, Australia

[10]Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales,

Australia

[11]Department of Orthopaedic Surgery, Duke University, Durham, North Carolina, USA

[12]Duke Cancer Institute, Duke University, Durham, North Carolina, USA

[13]Division of Medical Oncology, Department of Medicine, Duke University, Durham, North

Carolina, USA

[14]Department of Pathology, Stanford University, Stanford, California, USA

[15]Department of Radiation Oncology, UPMC Hillman Cancer Center-University of Pittsburgh,

Pittsburgh, Pennsylvania, USA

[16]Department of Surgery, Duke University, Durham, North Carolina, USA

[17]Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network,

Toronto, Ontario, Canada

[18]Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

[19]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

[20]Stanford Cancer Institute, Stanford University, Stanford, California, USA

[#]These authors contributed equally

*Corresponding authors

Contact Information

Everett J. Moding, M.D., Ph.D., Assistant Professor, Department of Radiation Oncology,

Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, California, 94305-5847, United

States of America. Email: emoding@stanford.edu. Phone: 650-498-1625.

and

David G. Kirsch, M.D., Ph.D., Professor, Department of Radiation Oncology, University of

Toronto, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada. Email:

david.kirsch@uhn.ca. Phone: 416-946-2094.

Conflicts of Interest

Y.M.M., K.V.B., K.J.W., D.G.K., and E.J.M. report grant funding from Stand Up to Cancer through the Merck Catalyst Program to their institutions to support this study. A.M.H has served as a paid consultant for Bayer and Telix. R.F.R. reports the following disclosures: Ownership: Limbguard, LLC (Spouse/Owner); Institutional Clinical Research Support: AADi, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, Intensity Therapeutics, Oncternal, PTC Therapeutics, SARC, Servier, SpringWorks, Tracon; Consultant/Advisor: AADi, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, EMD Seroro, GlaxoSmithKline, Ipsen, NanoCarrier, Replimmune, SpringWorks Therapeutics; Travel: Deciphera, SpringWorks Therapeutics. D.G.K. is a member of the scientific advisory board and owns stock in Lumicell Inc, a company commercializing intraoperative imaging technology. D.G.K. is a co-founder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. None of these affiliations represents a conflict of interest with respect to the work described here. D.G.K. is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. XRAD Therapeutics, Bristol Myers Squibb, and Varian Medical Systems provided research support in the past to D.G.K., but this did not support the research described here. E.J.M. has served as a paid consultant for Guidepoint and GLG. The other authors declare no competing interests.

Abstract

The addition of pembrolizumab to preoperative radiotherapy (RT) improved disease-free survival (DFS) for patients with stage III undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS) in the randomized SU2C-SARC032 trial. To precisely identify patients who benefit from pembrolizumab and RT, we performed comprehensive multi-omics profiling of pre- and post-treatment tumor and blood samples, including bulk RNA-seq, flow cytometry, and cytometry by time of flight. Additionally, we built a single-cell RNA-seq atlas spanning 65,786 cells from UPS and LPS to recover single-cell states in bulk tumor samples using digital cytometry. Two opposing tumor microenvironments (TMEs), immune-cold sarcoma ecotype 1 (SE1) and immune-hot sarcoma immune class E (SIC E), benefited from pembrolizumab. Pembrolizumab combined with RT depleted PD-1+ exhausted T cells in SIC E sarcomas and increased effector memory CD4+ T cells in SE1 sarcomas with an overall increase in CD8+ early activated T cells, CD4+ follicular helper T cells, and T cell receptor diversity. Matrix-remodeling stromal and epithelial-like sarcoma cell programs were associated with worse outcomes and diminished with pembrolizumab and RT. Our findings identify different mechanisms of response to pembrolizumab in localized, high-risk UPS/LPS and suggest that sarcoma TME signatures may identify patients most likely to benefit from adding pembrolizumab to preoperative RT.

Introduction

Soft tissue sarcomas (STS) are a rare and heterogeneous group of mesenchymal

malignancies[1]. Management for patients with high-risk, localized disease usually involves a

combination of preoperative radiotherapy (RT) followed by surgery to optimize local control[2].

However, approximately half of patients with high-risk features, including large tumor size (> 5

cm) and high grade, ultimately develop metastatic disease[3] with median overall survival of less

than 2 years[4]. To reduce risk of metastasis, cytotoxic chemotherapy has been administered

perioperatively to patients with high-risk localized STS with mixed results[5,6]. In the metastatic

setting, immune checkpoint inhibition (ICI) targeting programmed cell death protein 1 (PD-1)

and cytotoxic T-lymphocyte antigen-4 (CTLA-4) has shown promising activity in select STS

histologies such as undifferentiated pleomorphic sarcoma (UPS) and pleomorphic or

dedifferentiated liposarcoma (LPS)[7–9]. Furthermore, preclinical and clinical data have suggested

that ICI can synergize with RT to improve local and distant anti-tumor responses[10,11].

Recently, the SU2C-SARC032 phase 2 randomized trial investigated the benefit of

adding perioperative ICI to preoperative RT and surgery for patients with Stage III (>5 cm and

grade 2 or 3) UPS or LPS of the extremity or limb-girdle[12]. In the trial, 143 patients were

randomized to preoperative RT then surgery (control) or preoperative pembrolizumab with RT

then surgery and postoperative pembrolizumab (experimental). Remarkably, pembrolizumab

improved the 2-year disease-free survival (DFS) by 15% from 52% in the control arm to 67% in

the experimental arm, mainly driven by a reduction in distant disease recurrence. However,

pembrolizumab increased the risk of grade 3 adverse events from 31% to 56%, and most

patients did not benefit from pembrolizumab. Improvement in DFS was predominantly driven by

patients with grade 3 disease, but additional biomarkers will be critical to identify the patients

with stage III STS most likely to benefit from pembrolizumab.

Due to their mesenchymal origin, STS cells form complex interactions with other stromal

cells in the tumor microenvironment (TME), which might explain the poor performance of PD-L1

expression and tumor mutational burden for predicting ICI response in patients with STS[13].

Several prior studies have demonstrated that the sarcoma TME has prognostic value and can

potentially predict response to ICI[14,15]. For example, a previous study estimated the abundance

of nine stromal cell populations by deconvoluting bulk gene expression data to define five

sarcoma immune classes (SICs)[14,16]. Of these, SIC E, characterized by an inflamed TME with

abundant B-cells and tertiary lymphoid structures (TLS), was associated with improved

outcomes in patients with metastatic STS receiving pembrolizumab. We previously used a

machine learning method called EcoTyper[17] to identify three STS-specific cellular communities

of co-occurring transcriptional cell states (sarcoma ecotypes, SEs) that were associated with

prognosis and predicted response to immunotherapy across independent cohorts in metastatic

STS[15]. However, it is unclear if these predictors can identify patients with localized sarcomas

who could benefit from the addition of perioperative ICI to preoperative RT.

Here, we perform a comprehensive multi-omics analysis of samples from patients

enrolled in the SU2C-SARC032 trial to elucidate sarcoma TME dynamics in response to RT with

or without ICI and to identify predictors of benefit from pembrolizumab. We identify two distinct

TME signatures associated with better outcomes after pembrolizumab and provide evidence

that RT promotes intratumoral inflammation that may synergize with ICI to trigger anti-tumor

immune responses in immune cold STS. If validated in future studies, our findings could help to

identify patients with localized STS most likely to benefit from pembrolizumab to prevent the

development of metastatic disease.

Results

Correlative multi-omics analysis of SU2C-SARC032 patient samples

Patients in the SU2C-SARC32 trial were enrolled between November 28, 2017 and

November 14, 2023 and randomized to neoadjuvant RT (50 Gy in 25 fractions) followed by

surgical resection (control) or neoadjuvant RT with pre- and postoperative pembrolizumab

(experimental, **Fig. 1**). A total of 143 patients were enrolled in the trial, and 127 evaluable

patients were included in the modified intention-to-treat analysis (**Supplementary Fig. S1a**).

Three evaluable patients did not undergo surgery, two had disease progression before surgery,

and one patient on the experimental arm discontinued treatment due to adverse events. No

evaluable patients received adjuvant chemotherapy. Formalin-fixed paraffin-embedded (FFPE)

pre-treatment tumor biopsies and surgical resection specimens were analyzed with bulk RNA-

sequencing (RNA-seq). Overall, bulk RNA-seq data was available for 119 of 127 (94%)

evaluable patients with 70/119 (59%) patients having both pre-treatment biopsy and surgical

resection RNA-seq data. RNA-seq was available only for the pre-treatment time point in 41/119

(34%) and only on the surgical resection sample in 8/119 (7%). Fresh post-treatment surgical

resection samples were obtained for 56/127 (44%) patients and processed through flow

cytometry. Peripheral blood mononuclear cells (PBMC) samples were collected longitudinally for

Cytometry by Time of Flight (CyTOF) analysis in 55 patients before starting treatment ("pre-

treatment"), one week after starting treatment ("1 week on-treatment"), during the 3rd week of RT

("Week 3 of RT"), after neoadjuvant treatment and before surgery ("Post-RT/Pre-Surgery"), and

at 3 and 12 months after surgery. Follow up data was updated on February 24, 2025 for the

correlative analyses.

Baseline sarcoma TME signatures correlate with outcomes

Based on the established association between SICs and SEs with patient outcomes in

localized STS and response to ICI in patients with metastatic STS[14,15], we investigated if these

STS TME signatures were associated with outcomes in patients enrolled in SU2C-SARC032. To

answer this question, we assigned each patient to an SIC and an SE based on bulk RNA-seq of

their pre-treatment sample (**Supplementary Table S1**). Of the 111 patients with pre-treatment

RNA-seq, 10/111 (9%) patients were classified as SIC A, 39/111 (35%) as SIC B, 11/111 (10%)

as SIC C, 25/111 (22%) as SIC D, and 26/111 (23%) as SIC E (**Fig. 2a**). Consistent with the

prior report[14], patients classified at baseline as SIC E, which is characterized by a rich pro-

inflammatory immune infiltrate, had better DFS than patients classified as any other SIC (hazard

ratio [HR]: 0.36; 95% confidence interval [CI] 0.19, 0.67; nominal P = 0.01, **Fig. 2b**,

Supplementary Fig. S2a). Additionally, when considering only SIC E patients, those receiving

pembrolizumab had a better DFS compared to those receiving RT alone (HR: 0.37; 95% CI

0.07, 1.85; nominal P = 0.23, **Fig. 2c**). In contrast, among patients belonging to any other SIC

than SIC E, there was little difference in DFS between those in the control versus experimental

arm (HR: 0.86; 95% CI 0.47, 1.55; nominal P = 0.59, **Fig. 2d**).

Next, we applied the EcoTyper framework to assign patients to one of the three

previously defined SEs based on the pre-treatment tumor RNA expression profile (**Fig. 2e**). Of

note, a subset of patients (n = 66) had a high abundance of multiple SEs and were not assigned

to a dominant SE. Consistent with our prior report[15], patients assigned to SE3 had worse DFS

than patients assigned to SE2 (HR: 5.4; 95% CI 1.3, 22.8; nominal P = 0.02, **Fig. 2f**). This is

consistent with SE2 usually being enriched for activated pro-inflammatory immune cell states,

whereas SE3 tends to be enriched for immunosuppressive cell states such as *SPP1*+ M2-like

tumor-associated macrophages. Interestingly, there was improved DFS in patients with SE1 that

received pembrolizumab compared to those receiving RT only (HR: 0.39; 95% CI 0.12, 1.3;

nominal P = 0.10, **Fig. 2g**), while there was minimal difference in DFS between non-SE1

patients treated with pembrolizumab and those treated with RT only (HR: 0.95; 95% CI 0.51,

1.79; nominal P = 0.88, **Fig. 2h**). Notably, SE1 sarcomas are immune cold tumors with low

proportions of activated immune cells, and we previously observed low response rates to ICI in

patients with metastatic SE1 tumors[15]. Because patients with grade 3 tumors appeared to derive

most of the benefit from pembrolizumab in SU2C-SARC032[12], we evaluated whether there was

a difference in the proportion of grade 2 and 3 tumors based on SIC or SE classification. Grade

2 tumors were more abundant in SIC A compared to SIC B patients (**Fig. S2b**, 60% versus 23%,

respectively, nominal P = 0.049), and SE2 compared to SE3 patients (**Fig. S2c**, 56% versus

0%, respectively, nominal *P* = 0.02). However, neither SIC E nor SE1 were enriched for grade 3

versus grade 2 tumors.

Next, we measured the expression of 18 genes comprising a T cell-inflamed gene

expression profile (GEP), which was previously associated with response to pembrolizumab in

patients across 9 different cancers[18] (**Supplementary Table S2**). The pre-treatment T cell-

inflamed GEP score was associated with longer DFS in patients that received pembrolizumab

(HR: 0.62; 95% CI 0.4, 0.6; nominal *P* = 0.02, **Fig. S2d**). Interestingly, the T cell-inflamed GEP

score was higher in patients belonging to SIC E compared to any other SIC except SIC D (mean

T cell-inflamed GEP: SIC E 4.7, SIC D 4.11, SIC C 3.3, SIC B 2.9, SIC A 1.9; nominal *P* <

0.0001, **Fig. S2e**), but the T cell-inflamed GEP score was lower for patients classified as SE1

compared to SE2 or SE3 (mean T cell-inflamed GEP 2.5, 4.7, 3.9, respectively; nominal *P* <

0.0001, **Fig. S2f**). Lastly, we determined if pre-treatment expression of either immune

checkpoint molecules or T cell co-stimulatory molecules was associated with DFS in patients in

the control and experimental arms (**Fig. S2g**). Interestingly, we found that high *CTLA4* (HR: 0.3;

95% CI 0.1, 0.8; nominal *P* = 0.02) and high *TIGIT* (HR: 0.3; 95% CI 0.1, 0.8; nominal *P* = 0.01)

expression correlated with longer DFS only in patients that received pembrolizumab, but not in

those that received RT only (**Fig. S2h** and **S2i**). Overall, these findings confirm the association

of SICs and SEs with prognosis in high-risk, localized STS and suggest that two TME

signatures (immune hot SIC E and immune cold SE1) identify different subsets of patients who

benefit from the addition of perioperative pembrolizumab to preoperative RT and surgery.

Flow cytometry reveals post-treatment TME architecture

For patients with viable fresh tumor specimens collected after neoadjuvant therapy at the

time of surgical resection, flow cytometry was used to measure treatment effect on tumor

immune cell infiltration (**Fig. 3**, **Supplementary Tables S3** and **S4**). Within the CD4$^+$ T cell

population, there was a lower proportion of CD45RA$^+$ CCR7$^+$ naïve T cells (median 0.008 vs

0.02, nominal P = 0.004, q = 0.02), and CD279$^+$ (PD-1$^+$) T cells (median 0.34 vs 0.48, nominal P

= 0.005, q = 0.02) in patients that received neoadjuvant pembrolizumab and RT compared to

those that received RT only (**Fig. 3a** and **3b**). Because pembrolizumab binds to CD279, it is

possible that the lower proportion of CD279$^+$ T cells was due to antigen masking by

pembrolizumab. Additionally, there was a higher proportion of CD152$^+$ (CTLA4$^+$) CD4$^+$ T cells

(median 0.33 vs 0.22, nominal P = 0.04, q = 0.12) and activated (CD38+ HLA-DR+) CD4$^+$ T

cells (median 0.016 vs 0.008, nominal P = 0.06, q = 0.15) in patients treated with

pembrolizumab plus RT compared to RT only. Considering only patients classified as SE1 at

baseline, at post-treatment there was lower abundance of CD45RA$^-$ CCR7$^+$ central memory

(Tcm) CD4$^+$ T cells (median 0.22 vs 0.67, nominal P = 0.004, q = 0.04) and higher abundance of

CD45RA$^-$ CCR7$^-$ effector memory (Tem) CD4$^+$ T cells (median 0.76 vs 0.24, nominal P = 0.004,

q = 0.04) in those receiving pembrolizumab compared to those treated with RT only (**Fig. 3c**

and **3d**). In contrast, in patients classified as SIC E at baseline, there was a post-treatment

reduction in PD-1$^+$ CD4$^+$ T-cells (median 0.28 vs 0.64, nominal P = 0.02, q = 0.14) and an

increase in CM CD4$^+$ T cells (median 0.47 vs 0.33, nominal P = 0.05, q = 0.22).

Similar to CD4$^+$ T cells, we observed a lower proportion of PD-1$^+$ T cells (median 0.37 vs

0.49, nominal P = 0.03, q = 0.23) and naïve T cells (median 0.01 vs 0.03, nominal P = 0.04, q =

0.23) among CD8$^+$ T cells in patients treated with pembrolizumab (**Fig. S3a** and **S3b**). Subgroup

analysis of patients categorized as SE1 at baseline again showed lower abundance in the Tcm

subset within the CD8$^+$ T cell population (median 0.11 vs 0.39, nominal P = 0.03, q = 0.62) and

an increase in Tem CD8$^+$ cells (median 0.78 vs 0.42, nominal P = 0.08, q = 0.65). In baseline

SIC E patients, there was no post-treatment difference in Tcm (median 0.19 vs 0.11, nominal P

= 0.61, q = 0.99) or Tem (median 0.63 vs 0.56, nominal P = 0.39, q = 0.92) CD8+ T cells by flow

cytometry (**Fig. 3e** and **3f**). Looking at subsets of T-regs in post-treatment specimens, there was

a lower proportion of PD-1$^+$ cells in patients in the experimental compared to the control arm,

which was true both when considering all patients (**Fig. S3c** and **S2d**) and when considering

only those classified as SIC E at baseline (**Fig. S3e** and **S3f**).

Next, we determined the association of post-treatment abundance of the different

immune cell subsets identified by flow cytometry with DFS (**Fig. 3g**). Interestingly, the

abundance of CD8$^+$ Tcm-cells was associated with worse DFS both when considering patients

in the experimental and control arms (HR: 12.7; 95% CI 2.2, 71.4; nominal P = 0.004) and when

considering only patients treated with pembrolizumab (HR: 10.2; 95% CI 1.1, 94.0; nominal P =

0.04). However, the fraction of CD8+ T cells among total CD45+ cells was associated with better

DFS in the control arm only (HR: 0.04; 95% CI 0.002, 0.92; nominal P = 0.04). Lastly, we found

that abundance of CD103+ tissue-resident memory T cells was associated with improved DFS

only in patients in the control group (HR: < 0.001; 95% CI 1e-67, 0.0003; nominal P = 0.02),

while PD-1+ T-regs were associated with worse DFS in patients treated with pembrolizumab

and RT (HR: 10.7; 95% CI 1.02, 112.7; nominal P = 0.04). Overall, these results indicate that

the addition of pembrolizumab to neoadjuvant RT might result in an overall shift of tumor

infiltrating lymphocytes towards an effector phenotype. However, there were different dynamics

in baseline immune hot tumors (SIC E), where we predominantly observed depletion of

exhausted and immunosuppressive PD-1+ T cell subsets, and immune cold tumors (SE1),

where immunotherapy was associated with an increase in the proportion of Tem cells.

Longitudinal systemic immune monitoring through CyTOF

Peripheral blood (PB) immune cell profiling has been shown to correlate with response

to immunotherapy across different cancers[19]. Based on this, we asked if neoadjuvant RT with or

without pembrolizumab could result in systemic immune changes detectable in the PB of STS

patients that is associated with outcomes. We obtained PB samples before and at different

intervals after treatment both for patients receiving RT alone and those receiving neoadjuvant

RT plus pembrolizumab. CyTOF was then used to measure changes in abundance of different

PBMC subsets over time (**Fig. 4**, **Supplementary Tables S5** and **S6**). Unsupervised clustering

revealed 9 major PBMC clusters including B cells, monocytes, CD4+ T cells, naïve CD8+ T

cells, effector CD8+ T cells, activated T cells, memory T cells, NK cells, and CD56+ NK cells,

and further sub-clustering of PB T cells revealed 11 sub-populations (**Fig. 4a** and **4b**).

Considering the PBMC clusters (**Fig. 4c**, **Supplementary Table S5**), there was a

reduction in the abundance of B cells between the pre-treatment time point and the 3rd week of

RT in both the control arm (mean centered log-ratio [CLR] 0.64 vs 0.24, nominal P = 0.03, q =

0.94) and the experimental arm (mean CLR 0.65 vs 0.20, nominal P = 0.01, q = 0.69). There

was a progressive reduction in circulating monocytes from the 3rd week of RT until one-year

post-surgery considering all patients (mean CLR 2.2 vs 1.6, nominal P = 0.0009, q = 0.01),

which was driven by those in the experimental arm (mean CLR 2.2 vs 1.6, nominal P = 0.009, q

= 0.69). In contrast, the abundance of Memory T cells increased at 1 week on-treatment in

patients in the RT plus pembrolizumab arm (mean CLR -2.9 vs -1.5, nominal P = 0.04, q = 0.92)

as opposed to patients that only received RT (mean CLR -2.7 vs -3.5, nominal P = 0.04, q =

0.94). Lastly, we observed a trend towards a higher abundance of circulating NK cells at 1 week

after initiating treatment in patients that received RT only compared to those that also received

pembrolizumab (mean CLR -0.6 vs -2.5, nominal P = 0.04, q = 0.36). Next, we determined if the

abundance of any of the identified PBMC clusters was associated with DFS at any of the time

points analyzed (**Fig. 4d**). Interestingly, abundance of circulating Effector CD8+ T cells at one-

year post-surgery was associated with higher progression risk when considering all patients

(HR: 10.4; 95% CI 1.4, 76.9; nominal P = 0.02).

Considering PB T cell subsets (**Fig. 4e**, **Supplementary Table S6**), activated CD4+ T

cells showed a decrease at 1 week on-treatment for patients that received pembrolizumab with

a subsequent return to pre-treatment levels at 3 months post-surgery (mean CLR -2.0 vs -1.5,

nominal P = 0.02, q = 0.98). In patients in the control arm, CD4+ Tcm cells decreased from the

3rd week of RT to the post-RT/pre-surgery time point (mean CLR -2.4 vs -3.7, nominal P = 0.03,

q = 0.98) with a subsequent increase at one-year post-surgery (mean CLR -3.7 vs -1.7, nominal

P = 0.003, q = 0.55). Also, the fraction of naïve CD4+ T cells was higher in the experimental

versus the control arm at 1-year post-surgery (mean CLR 2.5 vs 1.7, nominal P = 0.03, q =

0.40), while there was a trend for lower circulating T-regs in patients receiving pembrolizumab 1

week after starting treatment (mean CLR -0.3 vs 0.6, nominal P = 0.05, q = 0.59). Lastly, the

abundance of activated CD8+ T cells at 1 year post-surgery was associated with higher

progression risk when considering all patients (HR: 13.9; 95%CI 1.3, 147.0; nominal P=0.03,

Fig. 4f), while abundance of early activation CD8+ T cells at 3 months post-surgery (HR: 0.06;

95%CI 0.006, 0.6; nominal P=0.01) and abundance of a subset of naïve CD8+ T cells (c1) at 1

year post surgery (HR: 0.1; 95%CI 0.03, 0.7; nominal P=0.01) were associated with lower

progression risk, considering only patients in the experimental arm or all patients, respectively.

Overall, these results highlight both early and late post-treatment changes in relative abundance

of different PB immune cell subsets in patients with STS receiving immunotherapy and RT,

which might indicate activation of a systemic anti-tumor immune response.

Digital cytometry dissects pre-treatment STS TME cell states

312   To further dissect the cell states contributing to the STS TME before and after treatment,

we performed digital cytometry on the bulk gene expression obtained from the FFPE tumor

samples. We built a scRNA-seq atlas of UPS and LPS samples [20], identifying different malignant

and non-malignant TME cell states across 65,786 cells from 12 patients (**Fig. 5a**). Overall, we

identified 9 malignant cell states, 7 non-malignant mesenchymal cell states including cancer-

associated fibroblasts (CAFs) and endothelial cells, 17 lymphoid, and 12 myeloid immune cell

states (**Fig. S4a**, **Supplementary Tables S7** and **S8**). We derived a single-cell gene expression

signature matrix from the atlas to deconvolute the abundance of each cell state in bulk RNA-seq

samples with CIBERSORTx (**Supplementary Tables S9**, **S10**, and **S11**)[21]. To validate the

accuracy of our deconvolution strategy, we correlated the abundance of major immune cell

types in post-treatment tumor samples measured with CIBERSORTx versus flow cytometry and

observed good correlation despite the different tumor regions sampled and technical

approaches utilized (**Fig. S4b**).

Next, we determined the association of pre-treatment cell state abundance measured by

digital cytometry with DFS (**Fig. 5b**). Interestingly, a higher abundance of matrix CAFs, a subset

associated with extra-cellular matrix (ECM) remodeling and high expression of matrix proteins

including collagen genes (*COL1A1*, *COL1A2*, *COL3A1*) and matrix metalloproteinases

(*MMP2*)[22], was associated with worse DFS in the whole cohort (HR: 1.3; 95% CI 1.06, 1.7;

nominal *P* = 0.01) and in the control arm (HR: 1.3; 95% CI 1.01, 1.8; nominal *P* = 0.04).

Similarly, abundance of mesenchymal-like ECM remodeling sarcoma cells, a cell state with high

expression of ECM remodeling-related genes (*MMP2*, *COL6A3*, *COL1A2*), was associated with

worse DFS considering all patients (HR: 1.2; 95% CI 0.9, 1.4; nominal *P* = 0.05). Additionally,

we found that sarcoma cells with an epithelial-like expression profile were associated with worse

DFS both in the control (HR: 1.5; 95% CI 1.1, 2.0; nominal *P* = 0.01) and experimental (HR: 1.4;

95% CI 1.1, 1.9; nominal *P* = 0.02) arms and when considering all patients (HR: 1.4; 95% CI

1.2, 1.8; nominal *P* = 0.0007). Sarcoma cells with an undifferentiated mesenchymal-like

phenotype were associated with better DFS in all patients (HR: 0.7; 95% CI 0.6, 0.9; nominal *P*

= 0.001) and in the control arm (HR: 0.5; 95% CI 0.3, 0.8; nominal *P* = 0.006). Among immune

cell subsets, a higher abundance of B cells and plasma cells was associated with better DFS in

the whole cohort (HR: 0.5; 95% CI 0.4, 0.9; nominal *P* = 0.009), while macrophages with high

expression of the iron exporter *SLC40A1* and the selenium binding protein *SELENOP* were

associated with better DFS in all patients (HR: 0.6; 95% CI 0.4, 0.9; nominal *P* = 0.007) and

those in the control group (HR: 0.5; 95% CI 0.3, 0.9; nominal *P* = 0.01). Interestingly,

SELENOP[+] macrophages have been found to be enriched in patients with non-small cell lung

cancer responding to neoadjuvant chemoimmunotherapy, with spatial transcriptomics data

showing preferential localization of this macrophage subtype in TLSs[23].

Next, we asked if there was a difference in the abundance of the recovered cell states in

pre-treatment samples across SICs or SEs (**Fig. 5c** and **5d**, **Fig. S5a** and **S5b**). As expected,

pro-inflammatory immune cell states were enriched in SIC E compared to other SICs, including

B cells and plasma cells, activated CD8+ T cells (*HLA-DP/DQ/DR*, *CCL4/5*, and *NKG7+*),

GZMK+ CD8+ T memory cells, and CD56^{low} NK cells. We also observed enrichment of myeloid

cell subsets like amphiregulin-expressing dendritic cells (*AREG+* DCs)[24] and *SELENOP$^+$*

SLC40A1$^+$ macrophages in SIC E and SIC D and higher levels of exhausted CD8+ T cells

(*PDCD1*, *LAG3*, *HAVCR2*, *TOX*, and *ENTPD1+*) in SIC E samples, possibly indicating the

establishment of a chronic anti-tumor immune response leading to T cell dysfunction[25,26]. Lastly,

matrix CAFs and both epithelial and ECM-remodeling sarcoma cell states tended to be enriched

in the immune-cold SIC A and SIC B. Looking at cell states abundance across SEs, we noticed

enrichment of immunosuppressive myeloid cells in SE3 compared to SE2 and SE1 samples,

including monocytes expressing high levels of epiregulin (*EREG+*), reported to promote

tumorigenesis and invasion in gliomas[27], and immunoregulatory polymorphonuclear cells

(PMNs) with high expression of *AQP9* and *LUCAT1*. As expected, SE2 showed a higher

abundance of activated CD8+ T cells compared to SE1. Lastly, SE1 showed higher proportion

of myofibroblastic sarcoma cells, characterized by high expression of genes associated with

motility and cytoskeleton activity (*ACTA2*, *MYL9*, *ACTG2*), and lower abundance of *SELENOP$^+$*

SLC40A1$^+$ macrophages compared to SE2 and SE3, possibly signaling the lack of a pre-

existing anti-tumor immune response.

Overall, these results further indicate how SE1 and SIC E tumors represent distinct

sarcoma TME states. Indeed, only one patient was classified as both SE1 and SIC E at baseline

(**Fig. 5e**). Additionally, we compared the abundance of the different deconvoluted cell states

between SIC E and SE1 and found that SIC E tumors were enriched for both activated and

stressed/exhausted CD4+ and CD8+ T cell states, B cells and plasma cells, and CD56^{high} and

CD56^{low} NK cells (**Fig. 5f**). In contrast, SE1 sarcomas were enriched for both epithelial-like and

mesenchymal-like ECM remodeling sarcoma cell states and matrix CAFs. These results further

show that SE1 tumors harbor an immune-desert phenotype with little to no immune cell

infiltration, opposite to the rich immune infiltration of SIC E tumors. These TME differences were

also reflected in outcomes, where baseline SE1 patients had worse DFS compared to SIC E

patients across both treatment arms (HR: 2.62; 95% CI 1.0, 6.9; nominal *P* = 0.048, **Fig. 5g**).

Neoadjuvant RT plus ICI reshapes the sarcoma TME

Next, we aimed to define the effects of neoadjuvant RT with or without ICI on the STS

TME. When comparing pathologic response in the resection specimen after neoadjuvant

therapy in the experimental vs. the control arm, the addition of pembrolizumab increased the

percent necrosis (median 90% vs 74%, nominal *P* = 0.01, **Fig. 6a**). However, pathological

response was not associated with DFS in either arm when measured as a continuous variable

or by defining a pathological complete response as ≥ 95% necrosis (**Fig. S6a**). When

determining the association of post-treatment abundance of the cell states recovered through

CIBERSORTx with DFS (**Fig. 6b**), we found that abundance of *CD36*+ CAFs was associated

with better DFS in both the experimental group (HR: 0.48; 95% CI 0.2, 0.9; nominal *P* = 0.02)

and the whole cohort (HR: 0.66; 95% CI 0.5, 0.9; nominal *P* = 0.02), while a higher abundance

of matrix CAFs was associated with worse DFS (HR: 1.18; 95% CI 0.9, 1.5; nominal *P* = 0.13).

Also, higher abundances of both activated CD8+ T cells (HR: 0.61; 95% CI 0.4, 0.9; nominal *P* =

0.02) and CD4+ T naïve (Tn) cells (*CCR7*, *FOXP1*, *BACH2*+) (HR: 0.72; 95% CI 0.5, 0.9;

nominal *P* = 0.04) were associated better DFS in the whole cohort, and a higher naïve CD4+ T

cell abundance was associated with better DFS in the control group (HR: 0.63; 95% CI 0.4, 0.9;

nominal *P* = 0.03).

We also investigated associations between post-treatment expression of immune

checkpoint genes and DFS to highlight possible mechanisms of resistance to ICI plus RT (**Fig.**

S6b). Interestingly, we found that higher post-treatment expression of *PDCD1* (PD-1) was

associated with better DFS in patients that received pembrolizumab (HR:0.44; 95% CI 0.2, 0.8;

nominal P = 0.007), but not in those treated with RT alone (HR: 0.69; 95% CI 0.4, 1.0; nominal

P = 0.09, **Fig. S6b, S6c**). Higher expression of *NCR3LG1* was associated with worse DFS only

in patients that received pembrolizumab and RT (HR: 1.8; 95% CI 1.1, 2.8; nominal P = 0.02,

Fig. S6b, S6d). *NCR3LG1* codes for the immune checkpoint molecule B7-H6, which acts as an

activating ligand for the NK cell receptor NCR3[28] and has been found to be over-expressed on

mesenchymal cell lines sensitive to NK cell-mediated cytotoxicity[29]. Importantly, B7-H6

expression has also been shown to promote cytolysis of activated T cells by NK cells and might

be implicated in resistance to ICI[30]. Indeed, we found that patients with high post-treatment

expression of *NCR3LG1* also tended to have lower expression of *B2M* (a proxy for HLA class I

expression)[31] and *HLA-E,* indicating a state of increased sensitivity to NK cell killing and

reduced susceptibility to ICI[32] (**Fig. S6e** and **S6f**). Overall, these findings suggest avenues for

novel therapeutic combinations to improve response to pembrolizumab in combination with RT.

413   To better understand the effect of RT and pembrolizumab on STS, we performed

differential gene expression analysis and gene set enrichment analysis on the pre-treatment

and post-treatment samples from both arms. When accounting for the effect of pembrolizumab,

post-RT samples showed enrichment for gene sets associated with an inflammatory response,

including IFN-γ, IL-2, and IL-6 signaling, as well as gene sets associated with an anti-tumor

responses like allograft rejection and apoptosis (**Fig. 6c**). In patients treated with

pembrolizumab, we observed a down-regulation of genes associated with epithelial to

mesenchymal transition and MYC-regulated genes and an enrichment for genes associated

with normal myogenesis, which might reflect reduced proliferation and decreased abundance of

cancer cells (**Fig. 6d**).

423   We then queried if the addition of pembrolizumab to RT changed the overall composition

of the TME. First, we measured the treatment-related change in abundance of the cell states

recovered through CIBERSORTx (**Fig. 6e**). Interestingly, there was a decrease in matrix CAFs

and ECM remodeling mesenchymal-like sarcoma cells only in patients that received

pembrolizumab but not in the control arm and a more marked decrease in epithelial-like

sarcoma cells in the experimental versus the control arm. Also, CD8+ early activated T cells

(*CRTAM*, *EOMES*, and *ZEB2*+) and CD4+ T follicular helper cells (*CXCL13*, *BTLA*, *TNFRSF4*,

and *TNFRSF18*+) increased after treatment in patients treated with pembrolizumab, but not in

those that received RT only. CD4+ memory T cells (*CCR7*, *SELL*, *TCF7*, and *LEF1*+) and

SELENOP+ SLC40A1+ macrophages increased in both treatment arms. To see if these

differential changes in cell states were matched by changes in abundance of TME cellular

ecosystems, we measured abundance of sarcoma ecotypes before and after treatment in the

control and treatment arm (**Fig. 6f**, **Supplementary Table S12**). We observed a marked

decrease in the abundance of the immune cold SE1 in patients that received pembrolizumab

but not in those treated with RT alone and an increase in the immune hot SE2 that was more

pronounced in the experimental compared to the control arm.

Next, we measured the pre- and post-treatment T cell-inflamed GEP score in patients in

the control and experimental arms (**Fig. S6g**, **S6h**) and found a post-treatment increase in the T

cell-inflamed GEP score only in baseline SE1 patients receiving pembrolizumab plus RT (**Fig.**

6g). Similar results were observed when patients were grouped by SIC, where there was a

more pronounced increase in the T cell-inflamed GEP score post-treatment for SIC A or SIC B

tumors and mainly among patients receiving pembrolizumab (**Fig. S6i**). To test if these

differences in immune activation profiles also corresponded to differences in the T cell

repertoire, we reconstructed the T cell receptor (TCR) sequences from pre- and post-treatment

bulk RNA-seq samples using TRUST4[33] and found that patients categorized as SE1 at baseline

had lower TCR diversity compared to either SE2 or SE3 (**Fig. 6h**) and a trend towards lower

TCR diversity for SIC A versus SIC E (**Fig. S6j**). We observed an increase in TCR diversity post-

treatment only in patients receiving pembrolizumab and RT (**Fig. 6i**).

Given the observed benefit of pembrolizumab in SU2C-SARC032 for patients with grade

3 disease[12], we asked if combining tumor grade with baseline SIC and SE classification could

better identify patients that would benefit the most from pembrolizumab. Interestingly, we found

that patients classified as either SIC E or SE1 that also had grade 3 tumors showed a DFS

benefit from the addition of pembrolizumab (**Fig. 6j**, HR: 0.26; 95% CI 0.09, 0.8; nominal P =

0.03), while those with grade 2 disease or classified as non-SIC E and non-SE1 did not appear

to benefit from immunotherapy (**Fig. 6k**, HR: 1.18; 95% CI 0.6, 2.3; nominal P = 0.62,

interaction P = 0.03). Taken together, these results support a model where the addition of

pembrolizumab to neoadjuvant RT induces immune activation in immune cold SE1 sarcoma

while also reigniting an established yet dysfunctional pre-existing anti-tumor response in

immune hot SIC E sarcomas.

Discussion

In this study, we performed a comprehensive multi-omics assessment of patients with

stage III LPS or UPS of the extremity receiving neoadjuvant RT with or without perioperative

pembrolizumab as part of SU2C-SARC032[12]. Our analyses revealed two distinct baseline STS

TME states associated with benefit from the addition of pembrolizumab to neoadjuvant RT. We

found that both an immune desert state, corresponding to SE1, and an immune hot TME,

represented by SIC E, correlated with clinical benefit from the addition of pembrolizumab to RT.

This observation likely indicates complementary mechanisms of benefit from ICI and RT[34].

Similar to other solid tumors that respond to ICI[35], the presence of an established anti-

tumor immune response in SIC E STSs was associated with benefit from the addition of

immunotherapy to RT. SIC E tumors are characterized by high expression of gene signatures

related to CD8+ and CD4+ T cells, NK cells, and B cells and are enriched for TLS on IHC,

indicating a robust chronic anti-tumor response[14]. Our deconvolution strategy provides a high-

resolution view of the cellular states that contribute to defining SIC E and is consistent with prior

observations that SIC E STSs might be primed for benefiting from anti-PD-1/PD-L1 agents[14,15].

Flow cytometry analyses on post-treatment samples in this study revealed that, in SIC E tumors,

the addition of ICI to RT mainly resulted in depletion of likely exhausted PD-1+ CD8+ and PD-1+

CD4+ T cells, which could lead to a reinvigorated T cell effector function[36,37]. Additionally, while

the association between an SIC E TME state and benefit from ICI was previously demonstrated

in the metastatic setting[14], our results also indicate a clinical benefit from immunotherapy in

localized STSs with an immune hot TME. This is also consistent with data from a recent phase 2

randomized non-comparative trial (NCT03307616), which studied neoadjuvant nivolumab or

ipilimumab/nivolumab in patients with resectable retroperitoneal dedifferentiated LPS (DDLPS)

and neoadjuvant nivolumab combined with RT for patients with UPS of the extremity[38]. This

study showed that patients with DDLPS that received neoadjuvant ICI and showed presence of

TLS at surgery had improved overall survival and that baseline immune cell infiltration, rather

than PD-L1 expression, correlated with outcomes in both cohorts, which is consistent with our

observations.

At the same time, our study suggested a benefit from the addition of immunotherapy for

patients with baseline SE1 tumors, which are typically immune cold with very little immune

infiltration, likely signaling lack of a pre-existing immune response[15]. Indeed, digital cytometry

revealed low baseline abundance of activated CD8+ T cells and *SLC40A1+ SELENOP+*

macrophages in SE1 tumors with a higher proportion of STS cell states, which is consistent with

the lack of anti-tumor immunity. After pembrolizumab and RT, SE1 tumors showed an increase

in CD4+ and CD8+ Tem cells by flow cytometry, indicating the induction of a *de novo* immune

response. Accordingly, we observed a post-treatment increase in the T cell-inflamed GEP score

only in baseline SE1 patients treated with the RT/ICI combination. This was accompanied by an

overall increase in TCR repertoire diversity and an increase in early activated CD8+ T cells and

CD4+ Tfh cells only in the experimental arm. Notably, SE3, which was associated with response

to ICI in patients with metastatic sarcomas[15], was not associated with benefit from

pembrolizumab in SU2C-SARC032. This suggests a different mechanism of response when ICI

is combined with radiotherapy or in patients with gross versus micrometastatic disease. Overall,

our findings support a model of synergism between RT and ICI, where RT induces immunogenic

cell death with release of damage associated molecular patterns (DAMPs) and cytokines, TME

inflammation, and improved antigen presentation, leading to accumulation of naïve T cells that

are then activated by ICI[39–41].

The clinical benefit of pembrolizumab in SU2C-SARC032 appeared to be driven by

patients with grade 3 tumors who have previously been shown to have a higher risk of

developing metastatic disease[42–44]. Our findings suggest that transcriptional biomarkers can be

integrated with tumor grade to more precisely identify patients benefiting from the addition of

pembrolizumab to preoperative RT in localized STS. Although this observation needs

prospective validation prior to incorporation into routine clinical management, an integrated

biomarker could help to balance the benefit-risk profile of ICI in the neoadjuvant setting due to

the increased incidence of grade 3 adverse events observed in the experimental arm of SU2C-

SARC032. Additionally, while this study only included LPS and UPS patients, our findings

demonstrate benefit from RT plus ICI in immune cold SE1 tumors, which have not been shown

to benefit from immunotherapy alone in the metastatic setting[15]. This suggests that it might

worthwhile to explore the synergism between RT and ICI in future studies in other high grade

STSs, which are generally considered to be refractory to immunotherapy in the setting of ICI

alone, such as leiomyosarcomas and synovial sarcomas[9]. Lastly, we acknowledge the

limitations of our study and correlative analyses, which are retrospective and exploratory in

nature. Our observations aim to be hypothesis-generating and will require validation in

independent cohorts and larger prospective clinical studies. A phase 3 randomized trial

(HARMONY) to validate the benefit of adding anti-PD-1 ICI to preoperative radiotherapy in

grade 3 UPS/LPS has been approved by the Canadian Clinical Trials Group (CCTG) and has

received funding from the Canadian Institute of Health Research (CIHR). This multi-institutional

clinical trial will provide an opportunity to validate the biomarkers identified in SU2C-SARC032.

In summary, we show that the sarcoma TME carries prognostic and predictive value in

patients with localized disease treated with preoperative RT and PD-1 blockade. If validated in

independent cohorts and prospective trials, sarcoma TME signatures could provide a

biologically relevant and sarcoma-specific biomarker to identify patients most likely to benefit

from the addition of ICI to neoadjuvant RT.

Materials and Methods

Clinical trial design

SU2C-SARC032 was an open-label, randomized, superiority phase II clinical trial.

Patients were enrolled at 20 academic institutions in Australia, Canada, Italy, and the United

States of America. The full original and final amended trial protocol and statistical analysis plan

with summaries of each amendment are available online in the appendix of the initial publication

of the trial results[12]. The trial was conducted by Sarcoma Alliance for Research Through

Collaboration (SARC) and funded by Stand Up to Cancer and Merck Sharp & Dohme.

Pembrolizumab was provided by Merck Sharp & Dohme. The study design was conceived by

the co-investigators and approved by Merck Sharp & Dohme. There was no patient or public

involvement in the design, conduct, or reporting of the trial. The funders of the study had no role

in data collection, data analysis, data interpretation, or writing of this report. SU2C-SARC032

was registered with ClinicalTrials.gov under NCT03092323 on March 27, 2017

(https://www.clinicaltrials.gov/study/NCT03092323).

Patients were eligible for enrollment if they were ≥12 years old with a resectable, non-

metastatic, grade 2 or 3 UPS (including myxofibrosarcoma) or dedifferentiated/pleomorphic LPS

of the extremity and an Eastern Cooperative Oncology Group performance status score of 0 or

1. Key exclusion criteria were prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent,

prior RT to the site of the sarcoma, concurrent active malignancy, active autoimmune disease or

infection, diagnosis of immunodeficiency or systemic immunosuppressive therapy, and planned

receipt of neoadjuvant or adjuvant chemotherapy. Full inclusion and exclusion criteria are

provided in the clinical trial protocol.

Patients were randomly assigned (1:1, stratified by tumor grade) to receive either

neoadjuvant RT (50 Gy in 25 fractions) followed by surgery (control group) or neoadjuvant

intravenous pembrolizumab (200 mg) for three doses before, during, and after neoadjuvant RT

followed by surgery and up to 14 doses of adjuvant pembrolizumab. The first dose of

pembrolizumab was within 7 days of enrollment, and RT started within 14 days of enrollment for

the control group or 1-14 days after the first pembrolizumab infusion for the experimental group.

Randomization was coordinated by the central clinical trial office at SARC using permuted block

randomization with random block sizes. The enrolling sites did not have access to the random

allocation sequence. Patients, physicians, and data analysts were not blinded to group

allocation.

Patient sample collection

Written informed consent was obtained for all patient data and samples obtained and

analyzed in this study. All human research in this study was conducted in accordance with the

Declaration of Helsinki. The SU2C-SARC032 study protocol was reviewed and approved by

SARC, Merck Sharp & Dohme, and the institutional review board at each institution participating

in the trial. The correlative analyses were approved by the institutional review boards at

Stanford University and Duke University.

Bulk RNA sequencing

RNA was extracted from FFPE pre-treatment core needle biopsies and surgically

resected tumors using RNAstorm FFPE RNA Extraction Kits (Cell Data Sciences). Tissue from

pre-treatment core needle biopsies was provided as pre-cut 5 μm slides from the treating site,

and RNA was extracted from 2-3 slides per patient. Surgically resected tumors were provided as

tissue blocks, and RNA was extracted from 2-3 one mm cores obtained from the region with the

highest sarcoma content based on pathologist review of hematoxylin and eosin-stained slides

from the block. Libraries were prepared for sequencing using SMARTer Stranded Total RNA-

Seq Kits v2-Pico Input Mammalian (Takara Bio) and sequenced with 150-bp paired-end reads

on a NovaSeq 6000 (Illumina). FASTQ files were quasi-aligned using Salmon[45].

Definition of sarcoma ecotypes and sarcoma immune classes

SIC centroids were defined based on UPS and LPS samples from TCGA using the SIC

labels provided by the authors[14]. Pre-processed bulk RNA-seq profiles from TCGA[46] were

downloaded and scaled to transcripts per million (TPM). TPM counts were log2-tranformed,

then analyzed using MCP-Counter[16] to measure the abundance of 10 tumor microenvironment

cell types. MCP-Counter scores were Z-score transformed across all samples for each cell type,

excluding fibroblasts. Samples were grouped by their assigned SIC, and the mean Z-score

abundance for each cell population was computed to create centroids for each SIC. Pre-

treatment bulk RNA-seq samples from SU2C-SARC032 were processed in the same manner

and assigned to the closest centroid based on Euclidean distance. Sarcoma ecotypes were

recovered and quantified using the EcoTyper reference-guided annotation framework [17] by

applying the previously learnt non-negative matrix factorization model[15] with TPM normalized

expression values as input.

Flow cytometry

Freshly isolated post-treatment tumors were disaggregated using the Human Tumor

Dissociation Kit Protocol (Miltenyi Biotec). Tumor cell suspensions were immediately viably

cryopreserved and stored in vapor phase liquid nitrogen until thawing prior to flow cytometry

analysis. All flow cytometry assays were performed in the Duke Immune Profiling Core (DIPC)

according to established Standard Operating Procedures (SOP) and in a strictly 'blinded'

manner. Viably cryopreserved tumor cell suspensions were thawed, washed, and enumerated

using a Muse Cell Analyzer. High parameter immune profiling was then performed using a 25-

channel custom flow cytometry panel to profile components of the tumor microenvironment

(**Table S4**). Cells were stained with a vital dye (Zombie Yellow Fixable Viability Kit, BioLegend)

along with Fc block (BD Biosciences) for 15 minutes at room temperature in the dark. Cells

were washed with FACSWash Buffer (D-PBS, ThermoFisher) containing 0.5% FBS. Cells were

then stained using a Cytokine/Chemokine Reagent (CCR) staining cocktail containing saturating

amounts of antibodies, washed, and subsequently stained with a surface staining cocktail

containing saturating amounts of antibody. Following surface staining, cells were washed,

permeabilized, and incubated with Fc block (BD Biosciences). After permeabilization, cells were

washed with eBioscience 1X Permeabilization Solution (ThermoFisher), incubated with Fc block

(BD Biosciences), washed, and stained with an intracellular staining cocktail. Following

intracellular staining, cells were washed, fixed with D-PBS containing 1% formalin, and acquired

using a calibrated and optimized BD FACSymphony A5 Cell Analyzer (BD Biosciences) within 6

hours of fixation. Compensation Beads (BD Biosciences) were stained for each monoclonal

antibody and used to correct for spectral overlap prior to gating analysis. FlowJo version 10.10.0

(BD Biosciences) was used to analyze the data using a gating template. An internal PBMC

batch control sample was included with each batch to detect potential batch-to-batch variation.

Gating was performed according to best practices with all gates set based on marker

expression of the batch control. Analysis gates were drawn for each panel as follows: 1) Time

gate was used to exclude air bubbles and clogs that might have occurred during acquisition for

all files, 2) Zombie Yellow Fixable Viability dye was used to exclude non-viable cells, and 3)

Singlet gating of both Forward and Side Scatter was used to exclude aggregates.

CyTOF

SU2C-SARC032 patient PBMCs collected prior to treatment, one week after starting

treatment, during the 3rd week of RT, after neoadjuvant treatment and before surgery, and at 3

and 12 months after surgery were viably frozen and stored in liquid nitrogen in the Duke

Substrate Services Core and Research Support facility. PBMCs from 2 healthy donors were

similarly utilized for Phytohaemagglutinin-stimulated (PHA-P; Invivogen) and non-stimulated

staining controls and viably frozen in aliquots for inclusion with each batch of patient samples to

identify any batch effects. PBMC phenotyping was conducted using a 35-marker mass

cytometric approach (**Table S13**). PBMCs were gently thawed in RPMI with 10% FBS

(ThermoFisher) and 50 mg/mL benzonase nuclease (Millipore Sigma). After thawing, PBMCs

were treated with Cell-ID Cisplatin in Maxpar PBS (Standard BioTools) for live-dead

discrimination. PBMCs were washed and then stained with Fc block (BD Biosciences) in

Maxpar Cell Staining Buffer (Standard BioTools) followed by anti-human CD45 with different

isotope conjugates utilized as barcodes for the SU2C-SARC032 samples and the spike-in

controls. CD45-stained control PBMCs were washed, spiked-in to SU2C-SARC032 samples,

and stained with the extracellular antibodies in the panel diluted in Maxpar Cell Staining Buffer

(Standard BioTools). PBMC samples were then barcoded with palladium isotopes (Standard

BioTools) and pooled prior to fixation and permeabilization with the respective eBioscience 1X

solutions (ThermoFisher). Batching was avoided for samples with low post-thaw viability

(viability < 70%). Samples were then stained with the intracellular antibodies in the panel diluted

in eBioscience 1X permeabilization solution (ThermoFisher). After staining and washing, cells

were again fixed with 1.6% formaldehyde and stained overnight with Cell-ID Intercalator in

Maxpar Fix and Perm (Standard BioTools) for singlet discrimination. Data acquisition was

performed on a Helios mass cytometer (Standard BioTools) according to manufacturer

instructions.

Data was debarcoded with the Standard BioTools provided software package and data

analyzed on Cytobank (Beckman). Geometric gating, iridium isotope gating, and cisplatin

gating were used to select for viable singlets. Raw CyTOF data was processed using the

"flowCore" Bioconductor R package[47]. Marker abundance was subset to the 35 measured

markers. Unstimulated and stimulated PBMC spike-in controls were segregated by different

CD45 isotope and excluded from clustering. The marker expression was arcsinh transformed

via the "CATALYST" package. Clustering was carried out using the Phenograph[48] based on the

top 30 principal components of marker expression. Hierarchical clustering of the median marker

expression of each initial cluster resulted in 9 distinct cell populations. This process was

repeated exclusively for the identified T cell clusters, which resulted in 11 distinct T cell

subtypes. UMAP embeddings were also derived from the principal components of the marker

data for visualization.

Given the compositional nature of PBMCs and T cells subsets fractions obtained through

CyTOF, where for each patient at each time point the fractions sum up to 1, centered log-ratio

transformation was applied on the raw fractions before downstream analysis using the

"compositions" R package[49].

STS single-cell RNA sequencing atlas

Previously published UPS, myxofibrosarcoma (MFS), and LPS (including both DDLPS

and well differentiated LPS) scRNA-seq samples were downloaded from GEO under accession

codes GSE279852 and GSE212527, and all analyses were performed in R using the "Seurat"

package[50]. Cells expressing hemoglobin genes, which usually represent artifacts or

contaminated cells, were removed from further analysis. Tumor and normal cells were

annotated for each sample as previously described[20], then malignant cells, CAFs, myeloid cells,

lymphoid cells, and endothelial cells (macro-groups) were identified separately for each

histology. Within each histology-specific macro-group, subclusters with an expression profile not

consistent with the macro-group of cells analyzed were removed from further analysis.

For each macro-group, the cells from each sample were normalized with SCTransform

using the glmGamPoi method[51] setting vst.flavor to "v2" followed by integration across samples

of all histologies using Harmony[52]. Dissociation induced genes (DIGs) obtained from Van Den

Brink et al.[53] and measured using Seurat's AddModuleScore, confounding from cycling cells

using Seurat's CellCycleScoring, and the percent of mitochondrial genes for each cell were

regressed out during SCTransform normalization. Objects were integrated using the top 3000

most variable features excluding DIGs, ribosomal protein genes, T cell receptor genes (for

lymphoid cell clustering), *MALAT1*, and cell cycle-specific genes to avoid confounding in

dimensionality reduction and clustering. Harmony was run using 15 dimensions and setting the

sample of origin as the blocking variable for batch effect correction. UMAP embeddings were

obtained using the first 15 Harmony dimensions, and subclusters were obtained by calculating

the k-nearest neighbors (k-NN) from a shared nearest-neighbor graph using the Louvain

algorithm implemented in the FindClusters function of the Seurat package at different

resolutions continuously from 0.4 to 2.0. The "clustree" R package[54] was used to determine the

optimal resolution for each macro-group. To label the final cell states, both FindAllMarkers and

limma-voom were used to perform differential gene expression testing and identify marker

genes for each subcluster. Seurat's FindAllMarkers was run with default parameters except for

min.pct = 0.25 and only.pos = TRUE. Limma-voom was run after converting the scRNA-seq data

to pseudobulks for each sample as previously described[55,56]. Cell states were defined by

comparing the identified marker genes within each cluster with the expression profile of known

cell states reported in the literature.

CIBERSORTx deconvolution of bulk RNA-seq data

Separate scRNA-seq signatures for immune and non-immune cells were built as above

and used as input to run CIBERSORTx in raw UMI counts format[21] with pre- and post-treatment

bulk RNA-seq tumor samples normalized to counts per million (CPM). CIBERSORTx was then

run in single cell mode using S-mode batch correction and setting the number of permutations

for p-value calculation to 500. The bulk RNA-seq data was then separately deconvoluted using

the TR4 signature matrix, which consists of immune, epithelial, endothelial, and fibroblast cells

derived from bulk RNA-seq of flow-sorted cellular populations[21]. The abundance of different cell

types recovered using the TR4 signature was used to normalize the abundance of immune and

non-immune single-cell states recovered using CIBERSORTx in single-cell mode, so that for

each sample, the total cell fractions summed to 1.0. Fractions were then centered log-ratio

transformed using the "compositions" R package[49] before downstream analysis.

Differential gene expression and gene set enrichment analysis

Differential gene expression analysis was performed using DESeq2[57] with treatment

arm, time point, and the interaction between the treatment arm and time point included in the

design. The effect of RT on gene expression (**Fig. 6B**) was analyzed by contrasting gene

expression in post-RT vs. pre-treatment samples, and the effect of pembrolizumab on gene

expression after treatment (**Fig. 6C**) was analyzed using the interaction term. Gene set

enrichment analysis for the Hallmark gene sets was performed for each comparison with the

"fgsea" R package with genes ranked by the $-\log_{10}$(p-value) multiplied by the sign of the $\log_2$(fold

change).

T cell receptor repertoire deconvolution

The T cell receptor repertoire for each sample was deconvoluted from raw bulk RNA-seq

FASTQ files using TRUST4[33]. A database of sequences for V, J, and C human genes was built

from the International ImMunoGeneTics information system and used for analysis[58].

Statistical analysis

The primary endpoint of SU2C-SARC032 was disease-free survival. SU2C-SARC032 was designed to detect a 22% increase in 2-year disease free survival from 50% in the control group to 72% in the experimental group with 80% power at a one-sided 0.05 level of significance. The protocol-defined primary statistical analysis plan was to compare disease-free survival between the two treatment groups using a stratified log-rank test in a modified intention-to-treat population that consisted of all evaluable patients. The prespecified significance level for the primary analysis was a one-sided *P* value of 0.05. Secondary outcomes included distant disease-free survival, local recurrence-free survival, overall survival, wound complications, and treatment-related adverse events as assessed by CTCAE v4.0. Exploratory outcomes included characterizing the peripheral and intra-tumoral immune response to combined pembrolizumab and RT and identifying predictors of clinical response to pembrolizumab and RT. On April 15, 2020, the protocol was amended to include a preplanned subgroup analysis to compare primary and secondary endpoints for patients in the control versus experimental arm for each sarcoma immune class. The study was not powered for secondary or exploratory analyses. A run-in safety analysis was performed after the first three patients were accrued to the experimental arm and observed for 30 days after cycle 3 of pembrolizumab to assess for grade 4 or greater toxicities. The primary endpoint analysis was triggered once 45 disease-free survival events were observed, and outcomes were masked to study investigators until this time. The primary and secondary outcomes, including all adverse events were reported previously[12]. Only evaluable patients were included in exploratory analyses, and patients with missing data were excluded.

The DFS interval was defined as the time from randomization to disease recurrence or death. Patients who were alive without documented disease recurrence were censored at the time of their last disease evaluation. For associations between cell subsets and DFS in samples

collected after randomization, we performed a landmark analysis to protect against guarantee-

time bias. Specifically, the DFS interval was calculated from the time of sample collection, and

patients that had a DFS event before the time of sample collection were excluded. In all cases,

DFS was calculated using the Kaplan-Meier method, and groups were compared using a two-

sided log-rank test. Hazard ratios were obtained by fitting univariable Cox proportional hazards

models using the coxph function from the "survival" R package, and the association of each

individual variable with DFS was calculated using two-sided Wald tests. Distributions of paired

samples were compared using paired Wilcoxon signed-rank tests, and distributions of unpaired

samples were compared using two-sided Wilcoxon rank-sum tests. When comparing

distributions of more than two groups, Kruskal-Wallis tests were used to test for overall

differences among groups, followed by post-hoc Dunn's tests for pairwise comparisons.

Proportions were compared using two-sided Fisher's exact tests. Correlations between

variables were measured using Spearman correlation. Multiple hypothesis testing correction

was performed using the Benjamini-Hochberg method. No threshold for significance was

prespecified due to the exploratory nature of the correlative analyses, and nominal P values

were reported. All analyses were performed either in R version 4.3.1 or using Prism 8

(GraphPad Software).

Data and code availability

The RNA sequencing data generated in this study have been deposited in the Database

of Genotypes and Phenotypes at phs003921.v1.p1 and will be made publicly available upon

publication. The scRNA-seq UPS/LPS atlas was built from previously published data available

from GEO through the accession code GSE279852 and GSE212527. The code used to perform

the analyses reported in the manuscript has been deposited at

https://github.com/StefTesta/SARC032_correlative. The EcoTyper code is available for nonprofit

academic use at https://github.com/ejmoding/sarcomaecotyper. All other datasets and

information necessary to replicate this work are provided in the supplementary tables. Any

additional information is available from the corresponding authors upon reasonable request.

Acknowledgements

We thank the patients and caregivers who participated in this study. We thank Denise

Reinke, Steven Young, Scott Okuno, and the research coordinators at SARC for supporting this

trial by collecting patient data and samples. In particular, we thank Erin Kozlowski and Meghan

Blalock who provided expert project management at SARC. We thank the UNC core for mass

cytometry that provided necessary equipment and materials for the CyTOF analysis. We also

thank the participating clinicians and clinical research teams at the participating sites for

enrolling patients to make this international trial and correlative studies possible. This work was

supported by a Stand Up To Cancer Catalyst Research Team grant with support from Merck

(DGK, KJW, EJM, and YMM), a research grant from the Investigator-Initiated Studies Program

of Merck Sharp & Dohme Corp (DGK), the National Cancer Institute (EJM: K08CA25542501;

DGK: R35CA197616), the Department of Defense (EJM: W81XWH-22-1-0161), the My Blue

Dots organization (EJM), the Tad and Diane Taube Family Foundation (MvR and EJM), and the

GPA Andrew Ursini Charitable Fund (AMH). The opinions expressed in this paper are those of

the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. The

schematic in Fig.1 was created with BioRender.com.

References

1.　Dufresne, A., Brahmi, M., Karanian, M. & Blay, J.-Y. Using biology to guide the treatment of

sarcomas and aggressive connective-tissue tumours. *Nat Rev Clin Oncol* **15**, 443–458

(2018).

2.   Von Mehren, M. *et al.* Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice

Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network* **20**, 815–

833 (2022).

3.   Wang, D. *et al.* Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma

Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of

Radiation Therapy Oncology Group RTOG-0630 Trial. *J Clin Oncol* **33**, 2231–2238 (2015).

4.   Tap, W. D. *et al.* Doxorubicin plus evofosfamide versus doxorubicin alone in locally

advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an

international, multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* **18**, 1089–

1103 (2017).

5.   Gronchi, A. *et al.* Histotype-tailored neoadjuvant chemotherapy versus standard

chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an

international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol*

18, 812–822 (2017).

6.   Blay, J.-Y. & Le Cesne, A. Adjuvant chemotherapy in localized soft tissue sarcomas: still not

proven. *Oncologist* **14**, 1013–1020 (2009).

7.   Tawbi, H. A. *et al.* Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma

(SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol*

18, 1493–1501 (2017).

8.   Burgess, M. A. *et al.* Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic

sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of

SARC028 expansion cohorts. *JCO* **37**, 11015–11015 (2019).

9.   Lee, A. Q., Hao, C., Pan, M., Ganjoo, K. N. & Bui, N. Q. Histologic and Immunologic Factors

Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma. *Clinical*

Cancer Research **31**, 678–684 (2025).

10. Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade

immunotherapy: radiosensitisation and potential mechanisms of synergy. *Lancet Oncol* **16**,

e498-509 (2015).

11. Wisdom, A. J. *et al.* Single cell analysis reveals distinct immune landscapes in transplant

and primary sarcomas that determine response or resistance to immunotherapy. *Nat*

Commun **11**, 6410 (2020).

12. Mowery, Y. M. *et al.* Safety and efficacy of pembrolizumab, radiation therapy, and surgery

versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity

(SU2C-SARC032): an open-label, randomised clinical trial. *Lancet* **404**, 2053–2064 (2024).

13. Keung, E. Z. *et al.* Correlative Analyses of the SARC028 Trial Reveal an Association

Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. *Clin*

Cancer Res **26**, 1258–1266 (2020).

14. Petitprez, F. *et al.* B cells are associated with survival and immunotherapy response in

sarcoma. *Nature* **577**, 556–560 (2020).

15. Subramanian, A. *et al.* Sarcoma microenvironment cell states and ecosystems are

associated with prognosis and predict response to immunotherapy. *Nat Cancer* **5**, 642–658

(2024).

16. Becht, E. *et al.* Estimating the population abundance of tissue-infiltrating immune and

stromal cell populations using gene expression. *Genome Biol* **17**, 218 (2016).

17. Luca, B. A. *et al.* Atlas of clinically distinct cell states and ecosystems across human solid

tumors. *Cell* **184**, 5482-5496.e28 (2021).

18. Ayers, M. *et al.* IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. *J*

Clin Invest **127**, 2930–2940 (2017).

19. Dyikanov, D. *et al.* Comprehensive peripheral blood immunoprofiling reveals five

immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer*

Cell **42**, 759-779.e12 (2024).

20. Testa, S. *et al.* SCAN-ACT: adoptive T cell therapy target discovery through single-cell

transcriptomics. *Genome Med* **17**, 89 (2025).

21. Newman, A. M. *et al.* Determining cell type abundance and expression from bulk tissues

with digital cytometry. *Nat Biotechnol* **37**, 773–782 (2019).

22. Cords, L. *et al.* Cancer-associated fibroblast classification in single-cell and spatial

proteomics data. *Nat Commun* **14**, 4294 (2023).

23. Cui, X., Liu, S., Song, H., Xu, J. & Sun, Y. Single-cell and spatial transcriptomic analyses

revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in

non-small cell lung cancer. *Mol Cancer* **24**, 111 (2025).

24. Bles, N., Di Pietrantonio, L., Boeynaems, J.-M. & Communi, D. ATP confers tumorigenic

properties to dendritic cells by inducing amphiregulin secretion. *Blood* **116**, 3219–3226

(2010).

25. Khan, O. *et al.* TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.

Nature **571**, 211–218 (2019).

26. Blackburn, S. D. *et al.* Coregulation of CD8+ T cell exhaustion by multiple inhibitory

receptors during chronic viral infection. *Nat Immunol* **10**, 29–37 (2009).

27. Chen, Y. *et al.* Tumor-associated monocytes promote mesenchymal transformation through

EGFR signaling in glioma. *Cell Reports Medicine* **4**, 101177 (2023).

28. Brandt, C. S. *et al.* The B7 family member B7-H6 is a tumor cell ligand for the activating

natural killer cell receptor NKp30 in humans. *J Exp Med* **206**, 1495–1503 (2009).

29. Sheffer, M. *et al.* Genome-scale screens identify factors regulating tumor cell responses to

natural killer cells. *Nat Genet* **53**, 1196–1206 (2021).

30. Kilian, M. *et al.* The immunoglobulin superfamily ligand B7H6 subjects T cell responses to

NK cell surveillance. *Sci. Immunol.* **9**, eadj7970 (2024).

31. Torrejon, D. Y. *et al.* Antitumor Immune Responses in B2M-Deficient Cancers. *Cancer*

Immunol Res **11**, 1642–1655 (2023).

32. Li, Y. *et al.* Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint

pathway in T cells and NK cells for cancer immunotherapy. *J Immunother Cancer* **12**,

e009934 (2024).

33. Song, L. *et al.* TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-

seq data. *Nat Methods* **18**, 627–630 (2021).

34. Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E. & Tuli, R. Radiation therapy and PD-1/PD-

L1 blockade: the clinical development of an evolving anticancer combination. *j.*

immunotherapy cancer **6**, 46 (2018).

35. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. *Science* **359**,

1350–1355 (2018).

36. He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. *Cell Res* **30**, 660–

669 (2020).

37. Kumagai, S. *et al.* The PD-1 expression balance between effector and regulatory T cells

predicts the clinical efficacy of PD-1 blockade therapies. *Nat Immunol* **21**, 1346–1358

(2020).

38. Roland, C. L. *et al.* A randomized, non-comparative phase 2 study of neoadjuvant immune-

checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal

undifferentiated pleomorphic sarcoma. *Nat Cancer* **5**, 625–641 (2024).

39. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in

cancer and infectious disease. *Nat Rev Immunol* **17**, 97–111 (2017).

40. Golden, E. B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M. H. & Formenti, S. C. The

convergence of radiation and immunogenic cell death signaling pathways. *Front. Oncol.* **2**,

(2012).

41. Buchwald, Z. S. *et al.* Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A

Critical Review on Timing, Dose and Fractionation. *Front. Oncol.* **8**, 612 (2018).

42. Haniball, J. *et al.* Prognostic factors and metastatic patterns in primary myxoid/round-cell

liposarcoma. *Sarcoma* **2011**, 538085 (2011).

43. Callegaro, D. *et al.* Development and external validation of two nomograms to predict

overall survival and occurrence of distant metastases in adults after surgical resection of

localised soft-tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol* **17**,

671–680 (2016).

44. Peiper, M., Zurakowski, D., Knoefel, W. T. & Izbicki, J. R. Malignant fibrous histiocytoma of

the extremities and trunk: an institutional review. *Surgery* **135**, 59–66 (2004).

45. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and

bias-aware quantification of transcript expression. *Nat Methods* **14**, 417–419 (2017).

46. Tatlow, P. J. & Piccolo, S. R. A cloud-based workflow to quantify transcript-expression levels

in public cancer compendia. *Sci Rep* **6**, 39259 (2016).

47. Ellis, B. *et al. flowCore: flowCore: Basic Structures for Flow Cytometry Data*. (2025).

48. Levine, J. H. *et al.* Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells

that Correlate with Prognosis. *Cell* **162**, 184–197 (2015).

49. Boogaart, K. G. van den, Tolosana-Delgado, R. & Bren, M. *Compositions: Compositional*

Data Analysis. (2024).

50. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of

single-cell gene expression data. *Nature Biotechnology* **33**, 495–502 (2015).

51. Ahlmann-Eltze, C. & Huber, W. glmGamPoi: Fitting Gamma-Poisson Generalized Linear

Models on Single Cell Count Data. *Bioinformatics*

https://doi.org/10.1093/bioinformatics/btaa1009 (2020) doi:10.1093/bioinformatics/btaa1009.

52. Korsunsky, I. *et al. Harmony: Fast, Sensitive, and Accurate Integration of Single Cell Data*.

(2023).

53. Van Den Brink, S. C. *et al.* Single-cell sequencing reveals dissociation-induced gene

expression in tissue subpopulations. *Nat Methods* **14**, 935–936 (2017).

54. Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at

multiple resolutions. *GigaScience* **7**, (2018).

55. Testa, S. *et al.* SCAN-ACT: Adoptive T Cell Therapy Target Discovery Through Single-Cell

Transcriptomics. Preprint at https://doi.org/10.1101/2025.01.18.633736 (2025).

56. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and

microarray studies. *Nucleic Acids Res* **43**, e47 (2015).

57. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for

RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

58. Lefranc, M.-P. *et al.* IMGT, the international ImMunoGeneTics information system. *Nucleic*

Acids Res **37**, D1006-1012 (2009).

Figure 1
a

Fig. 1: Overview of multi-omics tumor and peripheral blood analyses of patients treated in SU2C-SARC032. **a**, Patients were randomized to neoadjuvant radiotherapy followed by surgery (control) or 3 cycles of neoadjuvant pembrolizumab and radiotherapy followed by surgery and up to 14 cycles of adjuvant pembrolizumab (experimental). Bulk RNA was isolated from formalin-fixed paraffin embedded (FFPE) pre-treatment tumor biopsies and surgical resection tumor specimens prior to next-generation sequencing and digital cytometry to measure cell state abundances. Fresh surgical resection specimens after preoperative radiotherapy with or without pembrolizumab were dissociated prior to analysis with flow cytometry. Peripheral blood mononuclear cells (PBMCs) were isolated from longitudinal peripheral blood samples for analysis using cytometry by time-of-flight (CyTOF).

Figure 2

Fig. 2: Association of pre-treatment sarcoma microenvironment signatures with outcomes. a, Heat map of cell type abundances in the tumor microenvironment of pre-treatment sarcomas measured using MCP-counter. Samples are grouped by sarcoma immune class (SIC) assignment. (**b**, **c**, **d**), Kaplan-Meier curves showing disease-free survival (DFS) for (**b**) evaluable patients in SIC E versus all other SICs, (**c**) SIC E patients in the experimental versus control arm, and (**d**) non-SIC E patients in the experimental versus control arm. **e**, Heat map of cell state abundances in the tumor microenvironment of pre-treatment sarcomas measured using EcoTyper. Samples are grouped by sarcoma ecotype (SE) assignment. (**f**, **g**, **h**), Kaplan-Meier curves showing DFS for evaluable patients based on (**f**) SE assignment, (**g**) SE1 patients in the experimental versus control arm, and (**h**) non-SE1 patients in the experimental versus control arm. Only patients assigned to an SE are displayed in **f**, and patients not assigned to an SE are included in **g** and **h**. P-values were calculated using two-sided log-rank tests.

Figure 3

Fig. 3: Flow cytometry analysis of post-treatment samples. **a**-**f**, Heat maps showing the abundance of (**a**, **c**) CD4+ T cell, and (**e**) CD8+ T cell subsets in resected sarcomas after radiotherapy with or without pembrolizumab measured by flow cytometry. Patient samples are grouped according to study arm. Panels **c** and **e** include only patients classified as SIC E or SE1 at baseline. Violin plots comparing the abundance of select (**b**, **d**) CD4+ T-cell, and (**f**) CD8+ T-cell subsets in resected sarcomas after radiotherapy with or without pembrolizumab measured by flow cytometry. Panels **d** and **f** include only patients classified as SIC E or SE1 at baseline. P-values were calculated using a Wilcoxon rank-sum test. Multiple hypothesis testing correction was applied using the Benjamini-Hochberg method (q-value). **g**, Bar plot showing the association of cell subset abundance with disease-free survival in all evaluable patients (both) and patients treated on the control and experimental arms calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided Wald tests.

Figure 4

Fig. 4: Longitudinal CyTOF analysis of peripheral blood mononuclear cells (PMBCs). **a**, Unsupervised clustering of PBMCs (left) and T cell subsets (right) based on surface marker expression measured by CyTOF. 20,000 cells were randomly selected for plotting. **b**, Dot plot showing expression of surface markers in each cluster. **c**-**f**, Longitudinal changes in (**c**) PMBC subsets and (**e**) peripheral blood T cell subsets over time in the experimental and control arms. Plotted values represent centered log-ratio (CLR) normalized fractions of total PBMCs or T cells. P-values were calculated using two-sided Wilcoxon rank-sum tests. Multiple hypothesis testing

correction was applied using the Benjamini-Hochberg method (q-value). Heat maps showing the association of (**d**) PBMC subsets and (**f**) peripheral blood T cell subsets measured using CyTOF with disease-free survival in all evaluable patients and patients treated on the control and experimental arms calculated using univariate Cox proportional hazards models. P-values were computed using two-sided Wald tests without correction for multiple hypothesis testing. P-values < 0.05 are highlighted with an asterisk or a cross.

Fig. 5: Digital cytometry of the pre-treatment sarcoma microenvironment. **a**, UMAPs showing major cell type clusters and cell state subclusters defined from single cell RNA-sequencing (scRNA-seq) of undifferentiated pleomorphic sarcomas (UPS) and liposarcomas (LPS). This scRNA-seq atlas was used to create a signature matrix for digital cytometry of bulk RNA-seq data with CIBERSORTx. **b**, Bar plot showing the association of CIBERSORTx cell state abundances measured in pre-treatment biopsies with disease-free survival (DFS) in all evaluable patients (both) and patients treated on the control or experimental arms calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided

Wald tests without correction for multiple hypothesis testing. **c** and **d**, Differences in CIBERSORTx cell states abundance in pre-treatment samples across (**c**) sarcoma immune classes and (**d**) sarcoma ecotypes. Plotted values represent centered log ratio (CLR) normalized fractions. P-values shown were computed using a Kruskal-Wallis test and pairwise comparisons between SICs or SEs were computed using a Dunn's test (ns: P > 0.05; *: P <= 0.05; **: P <= 1e-2; ***: P <= 1e-3; ****: P <= 1e-4). P-value adjustment for multiple hypothesis testing was done using the Benjamini-Hochberg method (q-value). **e**, River plot showing overlap between sarcoma immune class E (SIC E) and sarcoma ecotype 1 (SE1). The thickness of the bars represents the proportion of patients in each group. **f**, Heat map showing CIBERSORTx cell states with different pre-treatment abundances between SIC E and SE1 sarcomas. P-values were calculated using two-sided Wilcoxon rank-sum tests and corrected for multiple hypothesis testing using the Benjamini-Hochberg method. **g**, Kaplan-Meier curves showing the DFS for evaluable patients assigned to SIC E versus SE1 based on pre-treatment RNA-sequencing. P-value was calculated using a two-sided log-rank test. MΦ: macrophages.

Figure 6

a Pathological response by treatment arm

b Association of post-RT cell state abundances measured by CIBERSORTx with disease-free survival

c Signifcantly enriched Hallmark gene sets after radiotherapy

d Signifcantly enriched Hallmark gene sets in patients treated with pembrolizumab

e Changes in CIBERSORTx cell state abundance post-RT by treatment arm

f Change in SE abundance post-RT

g Changes in T cell-inflamed GEP post-RT by SE

h Pre-treatment TCR repertoire diversity by SE

i TCR repertoire diversity pre- and post-RT in the control vs. experimental arm

j Grade 3 and SIC E/SE1

k Grade 2 or non-SIC E/SE1

Fig. 6: Effect of radiotherapy on the sarcoma microenvironment and an integrated predictor of benefit from pembrolizumab. a, Box plot comparing the post-treatment pathological response, measured as percent of tissue necrosis, in patients treated with RT alone versus those that received RT plus pembrolizumab. P value was obtained using a two-sided Wilcoxon rank-sum test. **b**, Bar plot showing the association of CIBERSORTx cell state abundances measured in post-radiotherapy (post-RT) surgically resected tumors with disease-free survival (DFS) in all evaluable patients (both) and patients treated on the control and experimental arms calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided Wald tests without correction for multiple hypothesis testing. **c** and **d**, Bar plots showing gene set enrichment analysis (GSEA) results comparing (**c**) post-RT versus pre-treatment samples accounting for the effect of pembrolizumab and (**d**) experimental versus control samples measured as the interaction of pembrolizumab with radiotherapy. **e**, Box-violin plots showing the post-RT change in non-immune (*left*) and immune (*right*) cell state abundances measured using CIBERSORTx in patients treated in the control and experimental arm. Plotted values represent centered log ratio (CLR) normalized fractions. P-values were computed using Wilcoxon signed-rank tests and were corrected for multiple comparisons using the Benjamini-Hochberg method. **f**, Box-violin plots showing the abundance of sarcoma ecotypes before and after treatment in patients in the experimental and control arms. P-values were computed using a Wilcoxon signed-rank test and corrected for multiple comparisons using the Benjamini-Hochberg method. **g**, Box-violin plots displaying the change in T cell-inflamed GEP scores described by Ayers et al. (*Journal of Clinical Investigation*, 2017) from pre-treatment to post-RT grouped by sarcoma ecotype and treatment arm. P-values were calculated using a Wilcoxon signed-rank test and adjusted for multiple hypothesis testing using the Benjamini-Hochberg method. **h** and **i**, Bar plots showing the T cell receptor repertoire diversity as computed using TRUST4 in (**h**) pre-treatment samples grouped by SE assignment or (**i**) comparing pre-treatment to post-treatment samples in the control versus experimental arm. P-values were obtained using a two-sided Wilcoxon rank-sum test. **j** and **k**, Kaplan-Meier curves showing DFS by treatment arm for (**j**) patients with grade 3 tumors assigned to SIC E or SE1 and (**k**) patients with grade 2 tumors or tumors not assigned to SIC E or SE1. P-values were calculated using a two-sided log-rank tests. MΦ: macrophages.

Figure S1

a

Fig. S1: CONSORT diagram. a, Flow diagram for the SU2C-SARC032 clinical trial. RT: radiotherapy, RNA-seq: RNA-sequencing, PBMC: peripheral blood mononuclear cells, CyTOF: Cytometry by Time of Flight.

Figure S2

a Patient outcomes by sarcoma immune class

b Tumor grade by sarcoma immune class

c Tumor grade by sarcoma ecotype

d Association pre-treatment T cell-inflamed GEP with patient outcomes

Patient Group	Cox DFS logHR (95% CI)	P-value
All Evaluable	−0.39 (−0.66 − −0.11)	0.006
Control	−0.31 (−0.68 − 0.06)	0.099
Experimental	−0.48 (−0.90 − −0.06)	0.024

e T cell-inflamed GEP by sarcoma immune class

f T cell-inflamed GEP by sarcoma ecotype

g Association of pre-RT immune checkpoint expression with outcomes

Gene	Cox DFS logHR (95% CI)	P-value
CTLA4 All Patients	−0.22 (−0.43 − −0.02)	0.033
CTLA4 Control	0.01 (−0.28 − 0.30)	0.937
CTLA4 Experimental	−0.42 (−0.73 − −0.11)	0.008
ICOS All Patients	−0.33 (−0.63 − −0.03)	0.031
ICOS Control	−0.16 (−0.58 − 0.25)	0.434
ICOS Experimental	−0.45 (−0.94 − 0.03)	0.069
LGALS9 All Patients	−0.26 (−0.45 − −0.08)	0.005
LGALS9 Control	−0.33 (−0.59 − −0.07)	0.013
LGALS9 Experimental	−0.18 (−0.46 − 0.10)	0.214
TIGIT All Patients	−0.21 (−0.39 − −0.02)	0.029
TIGIT Control	−0.05 (−0.33 − 0.23)	0.716
TIGIT Experimental	−0.35 (−0.62 − −0.07)	0.014
TNFSF14 All Patients	−0.19 (−0.39 − −0.00)	0.049
TNFSF14 Control	−0.04 (−0.31 − 0.23)	0.768
TNFSF14 Experimental	−0.34 (−0.64 − −0.04)	0.026

h

i

Fig. S2: Pre-treatment sarcoma microenvironment gene expression signatures. **a**, Kaplan-Meier curves showing disease-free survival (DFS) by SIC. P-values were calculated using two-sided log-rank tests. **b** and **c**, Proportion of patients with grade 2 or grade 3 tumors grouped by (**b**) sarcoma immune class (SIC) and (**c**) sarcoma ecotype (SE). P-values were calculated using two-sided Fisher's exact tests. **d**, Forest plot showing the association of the T cell-inflamed gene expression profile (GEP) described by Ayers et al. (*Journal of Clinical Investigation*, 2017) with DFS by treatment arm calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided Wald tests. **e** and **f**, Violin plots displaying the distribution of T cell-inflamed GEP scores grouped by (**e**) SIC and (**f**) sarcoma ecotype. P-values were calculated using a Kruskal-Wallis test and pairwise comparisons between SICs or SEs were computed using a Dunn's test (ns: $p > 0.05$; *: $p \leq 0.05$; **: $p \leq 1e\text{-}2$; ***: $p \leq 1e\text{-}3$; ****: $p \leq 1e\text{-}4$). **g**, Forest plot showing the association of immune checkpoint gene expression with DFS by treatment arm calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided Wald tests. **h** and **i**, Kaplan-Meier curves showing outcomes stratified based on pre-treatment (**h**) *CTLA4* and (**i**) *TIGIT* expression respectively. Gene expression is classified as high for a given sample if it is above the median for all pre-treatment samples. P-values were calculated using a two-sided Wald test.

Figure S3

Fig. S3: **Flow cytometry of post-treatment samples**. **a**-**f**, Heat maps showing the abundance of (**a**) CD8+ T cell and (**c**, **e**) regulatory T cell subsets in resected sarcomas after radiotherapy with or without pembrolizumab measured by flow cytometry. Patient samples are grouped according to study arm. Panel **e** includes only patients classified as SIC E or SE1 at baseline. Violin plots comparing the abundance of select (**b**) CD8+ T cell, and (**d**, **f**) regulatory T cell subsets in resected sarcomas after radiotherapy with or without pembrolizumab measured by flow cytometry. Panel **f** shows only patients classified as SIC E or SE1 at baseline. P-values were calculated using two-sided Wilcoxon rank-sum tests. Multiple hypothesis testing correction was applied using the Benjamini-Hochberg method (q-value).

Fig. S4: A single cell RNA-seq (scRNA-seq) reference atlas for bulk RNA-seq deconvolution of undifferentiated pleomorphic sarcomas (UPS) and liposarcomas (LPS). **a**, UMAP plots showing the different non-malignant and malignant cell states identified for each major cell type in the STS scRNA-seq reference atlas, including endothelial cells, cancer associated fibroblasts (CAFs), B cells, lymphoid, and myeloid cells. **b**, Scatter plots showing the

correlation between the abundance of cell types recovered in bulk RNA-seq of post-treatment formalin-fixed paraffin embedded (FFPE) samples using CIBERSORTx and measured through flow cytometry in the matched dissociated fresh tumor samples. Spearman's correlation coefficients and two-sided P-values are displayed on the graph. The line of best fit by linear regression and 95% confidence intervals are shown on the graph.

Figure S5

Fig. S5: Tumor microenvironment cell states across sarcoma immune classes and sarcoma ecotypes. **a** and **b**, Heat maps showing the abundance of cell states recovered with CIBERSORTx in pre-treatment samples grouped by (**a**) SIC and (**b**) SE. MΦ: macrophages.

Figure S6

Fig. S6: Association between immune checkpoint expression and outcomes and changes in the T cell-inflamed gene expression profile (GEP) post-radiotherapy (post-RT). **a**, Univariable Cox proportional hazards analysis measuring association of pathological response with DFS in patients in the control versus the experimental arm. Pathological response is measured as post-treatment percent necrosis, and it was used as either a continuous variable or dichotomized as a categorical variable using a cutoff of 95%. P-values were calculated using two-sided Wald tests. **b**, Forest plot showing the association of post-RT immune checkpoint gene expression with DFS by treatment arm calculated using univariable Cox proportional hazards models. P-values were calculated using two-sided Wald tests. **c** and **d**, Kaplan-Meier curves showing outcome interaction between post-RT (**c**) *PDCD1* and (**d**) *NCR3LG1* expression and treatment arm. Gene expression is classified as high for a given sample if it is above the median for all pre-treatment samples. P-values were calculated using a two-sided Wald test. **e** and **f**, Expression of (**e**) *B2M* and (**f**) *HLA-E* in post-treatment samples from the experimental arm grouped based on *NCR3LG1* expression, classified as high or low based on median expression. P-values were calculated using a two-sided Wilcoxon rank-sum test. Multiple hypothesis testing correction was applied using the Benjamini-Hochberg method (q-value). **g** and **h**, Heat maps showing the expression of genes in the T cell-inflamed GEP in pre-treatment and post-RT samples grouped by pre-treatment (**g**) sarcoma immune class (SIC) and (**h**) sarcoma ecotype (SE). **i**, Box-violin plots displaying the change in T cell-inflamed GEP score described by Ayers et al. (*Journal of Clinical Investigation*, 2017) from pre-treatment to post-RT grouped by sarcoma immune class and treatment arm. P-values were calculated using a Wilcoxon signed-rank test and adjusted for multiple hypothesis testing using the Benjamini-Hochberg method. **j**, Bar plots showing the T cell receptor repertoire diversity as computed using TRUST4 in pre-treatment samples grouped by sarcoma immune class assignment. P-values were obtained using Wilcoxon rank-sum tests.